When, if ever, will you utilize T-DM1 in metastatic HER2+ breast cancer given trastuzumab deruxtecan's significantly improved PFS vs T-DM1?  

The FDA recently approved trastuzumab deruxtecan (T-DXd) in the second line setting. Given the results of DESTINY-Breast03, what is now the role of TDM1 in the treatment armamentarium of HER2+ metastatic breast cancer? 

Can trastuzumab emtansine still be effective in sequence after progression on trastuzumab deruxtecan?



Medical Oncologist
Comments
Medical Oncologist at San Mateo Medical Center
Will you be using Trastuzumab deruxtecan (T-DXd) i...
Medical Oncologist at University of Iowa Holden Comprehensive Cancer Center
We have no data to support replacing T-DM1 with T-...
Medical Oncologist at San Mateo Medical Center
Thank you.
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice